Sugi Predict

Sugi Predict / Compounds / SCHEMBL29825652

SCHEMBL29825652

SCHEMBL29825652

CS(=O)(=O)c1ccccc1-c1ccc(NC(=O)c2cc(C(F)(F)F)nn2-c2cccc(CN)c2)c(F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 13/20 1.00
▸ PRSS1 P07477 9/20 1.00
▸ PRSS2 P07478 9/20 1.00
▸ PRSS3 P35030 9/20 1.00
▸ F2 P00734 9/20 1.00
▸ F9 P00740 2/20 1.00
▸ PROC P04070 2/20 1.00
▸ KLK1 P06870 1/20 1.00
▸ KLKB1 P03952 4/20 0.98
▸ CFH P08603 1/20 0.98
▸ CARM1 Q86X55 3/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31067656 1.00 F10 (1.00) F10PRSS1PRSS2PRSS3F2
SCHEMBL3052253 1.00 F10 (1.00) F10PRSS1PRSS2PRSS3F2
Hydrochloric Acid SCHEMBL29377504 0.99 F10 (1.00) F10PRSS1PRSS2PRSS3F2
SCHEMBL7742478 0.94 F10 (0.89) F10PRSS1PRSS2PRSS3F2
SCHEMBL13550922 0.93 F10 (1.00) F10PRSS1PRSS2PRSS3F2
SCHEMBL7749603 0.92 PRSS1 (0.88) F10PRSS1PRSS2PRSS3F2
SCHEMBL19706432 0.91 F10 (0.83) F10PRSS1PRSS2PRSS3F2
SCHEMBL14565397 0.89 CARM1 (1.00) F10PRSS1PRSS2PRSS3F2
SCHEMBL14565395 0.89 CARM1 (1.00) F10PRSS1PRSS2PRSS3F2
SCHEMBL3833378 0.86 F10 (0.80) F10PRSS1PRSS2PRSS3F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
US-12162838-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-12-10 — — US disclosed
US-12116346-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-10-15 — — US disclosed
CN-113307772-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2024-06-28 — — CN disclosed
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-05-09 — — US disclosed
US-11708332-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11708333-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-11685721-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-06-27 — — US disclosed
EP-4180424-A1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2023-05-17 — — EP disclosed
US-20230094305-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-03-30 — — US disclosed
US-20230100082-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-03-30 — — US disclosed
US-20230056538-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-02-23 — — US disclosed
EP-3828173-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2022-08-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230100082-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 F10 115/4885PRSS1 40/4885PRSS2 94/4885
US-12116346-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-20240150296-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-11708332-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 F10 115/4885PRSS1 40/4885PRSS2 94/4885
US-20230094305-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK1, KLK5 F10 118/4885PRSS1 29/4885PRSS2 65/4885
US-20230056538-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-20240150295-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-11708333-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 F10 118/4885PRSS1 29/4885PRSS2 65/4885
US-11685721-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885
US-12162838-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 F10 112/4885PRSS1 43/4885PRSS2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.